PROPELLING PRECISION MEDICINE FORWARD TO IMPROVE HEALTH FOR ALL
As a global Contract Research Organization Laboratory (CRO) to the biopharmaceutical industry,
CellCarta provides access to a broad offering of biomarker platforms and services. We partner with you to
address the most complex scientific testing needs, delivering customized biomarker testing solutions to
further the limitless potential of precision medicine.
CellCarta, which is under the private ownership of Arsenal Capital, is the union of scientific pioneers of the
CRO industry supporting discovery, translational and clinical research. At the core of CellCarta is the
fusion in 2019 of Caprion Biosciences and HistoGeneX which brought together a unique combination of
biomarker expertise focused on immune monitoring, histopathology, proteomics and genomics, including
the capabilities of previously acquired Primity Bio and Serametrix.
Leveraging its presence on four continents and through the addition of Clinical Logistics Inc. and Mosaic
Laboratories, which further expanded its specimen logistics services and biomarker franchise, CellCarta is
uniquely positioned to provide complex and customized clinical biomarker solutions at the global level.